Sonus Pharmaceuticals, Inc. - SNUS- Profile

SONUS Pharmaceuticals, Inc.. The Company's principal activity is to develop oncology drugs that provide better therapeutic alternatives for cancer patients, including improved efficacy, safety, tolerability and are more convenient to use. The Company's services includes develop proprietary formulations of cancer drugs utilizing its TOCOSOL technology, develop novel formulations of oncology related drugs and identify and acquire products/technologies that are complementary to our focus in oncology in order to broaden our business and market opportunities. The Company's novel vitamin E-based emulsion technology has been designed to address the challenges of poorly soluble cancer drugs. The technology uses vitamin E oil and tocopherol derivatives to solubilize and formulate drugs with the goal of enhancing their efficacy, safety and administration. The Company's TOCOSOL Paclitaxel, is a ready-to-use, injectable paclitaxel emulsion formulation. Develops oncology drugs that provide better therapeutic alternatives for cancer